Amylyx Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Bedrosian Camille L
Amylyx Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(4.53%)
Amylyx Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
Amylyx Pharmaceuticals | 8-K: Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results
Amylyx Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Klee Justin B.
Amylyx Pharmaceuticals | SC 13G: Statement of acquisition of beneficial ownership by individuals-The Vanguard Group(4.53%)
Amylyx Pharmaceuticals | SC 13G: Statement of acquisition of beneficial ownership by individuals-Perceptive Advisors LLC(6.5%),Joseph Edelman(6.5%), etc.
Amylyx Pharmaceuticals | 8-K: Current report
Amylyx Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Klee Justin B.
Amylyx Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Cohen Joshua B
Amylyx Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Bedrosian Camille L
Amylyx Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Mazzariello Gina
Amylyx Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Cohen Joshua B
Amylyx Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Cohen Joshua B
Amylyx Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer FRATES JAMES M
Amylyx Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Firestone Karen
Amylyx Pharmaceuticals | 4/A: Statement of changes in beneficial ownership of securities (and amendment thereto)-Officer FRATES JAMES M
Amylyx Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director MILNE GEORGE M JR
Amylyx Pharmaceuticals | SC 13G: Statement of acquisition of beneficial ownership by individuals-TCG Crossover GP II, LLC(6.8%),TCG Crossover Fund II, L.P.(6.8%), etc.
Amylyx Pharmaceuticals | 10-Q: Q2 2024 Earnings Report
No Data